Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (1345)

« Back to Publications

A retrospective analysis of the validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries

Jackson A. et al, (2024), The Lancet Oncology

Immune Microenvironment Modulation following Neo-adjuvant Therapy for Oesophageal Adenocarcinoma: A Translational Analysis of the DEBIOC Clinical Trial

Scanlon E. et al, (2024), ESMO Open

Risk Stratification in Older Intensively Treated Patients With AML.

Versluis J. et al, (2024), J Clin Oncol

LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorder.

Chettle J. et al, (2024), HGG Adv, 5

Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.

Aksöz M. et al, (2024), Sci Immunol, 9

Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK Biobank.

McCracken C. et al, (2024), JACC CardioOncol, 6, 575 - 588

Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

Cogswell TJ. et al, (2024), RSC Med Chem

Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.

Godfrey AL. et al, (2024), Br J Haematol

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.

Hamid O. et al, (2024), J Clin Oncol

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Jakobsen NA. et al, (2024), Cell Stem Cell

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.

Gerds AT. et al, (2024), Blood Adv

Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells.

Carrelha J. et al, (2024), Nat Immunol

Access divergence to new cancer medicines in the United Kingdom.

Lythgoe MP. et al, (2024), Eur J Cancer, 207

An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.

Baxter MA. et al, (2024), ESMO Open, 9

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML

Risueño A. et al, (2024), Leukemia Research, 140

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.

Luke JJ. et al, (2024), J Immunother Cancer, 12

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.

Elez E. et al, (2024), BMC Cancer, 24

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).

Spiliopoulou P. et al, (2024), J Exp Clin Cancer Res, 43

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.

Watson RA. et al, (2024), Journal for immunotherapy of cancer, 12

New role of fat-free mass in cancer risk linked with genetic predisposition.

Harris BHL. et al, (2024), Sci Rep, 14

1
2
3
4
5
6
7
...
»